| Quarterly Financials | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
Revenue  | 141 | 138 | 137 | 93 | 120 | 110 | 105 | 131 | 95 | 196 | 164 | 180 | 134 | 171 | 169 | 251 | 185 | 207 | 228 | 231 | 252 | 230 | 226 | 241 | 184 | 204 | 213 | 246 |
| Expenses | 148 | 133 | 129 | 108 | 100 | 91 | 108 | 123 | 95 | 116 | 151 | 154 | 119 | 147 | 146 | 177 | 161 | 175 | 185 | 188 | 212 | 192 | 191 | 210 | 159 | 195 | 213 | 211 |
| EBITDA | -7 | 6 | 7 | -15 | 21 | 19 | -3 | 8 | 0 | 79 | 13 | 26 | 15 | 24 | 23 | 74 | 24 | 32 | 43 | 42 | 40 | 38 | 35 | 32 | 26 | 9 | 0 | 35 |
| Operating Profit % | -9 % | -1 % | 0 % | -23 % | 16 % | 17 % | -5 % | -3 % | -3 % | 9 % | 7 % | 13 % | 10 % | 11 % | 9 % | 16 % | 12 % | 12 % | 16 % | 13 % | 13 % | 14 % | 12 % | 12 % | 8 % | -1 % | -3 % | 11 % |
| Depreciation | 31 | 32 | 32 | 23 | 30 | 30 | 29 | 20 | 20 | 20 | 20 | 27 | 22 | 18 | 8 | 7 | 8 | 8 | 9 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Interest | 0 | 0 | 3 | 1 | 14 | 13 | 13 | 12 | 11 | 10 | 7 | 5 | 8 | 9 | 8 | 8 | 6 | 4 | 4 | 4 | 4 | 3 | 4 | 4 | 3 | 4 | 3 | 3 |
| Profit Before Tax | -39 | -26 | -28 | -39 | -23 | -24 | -45 | -25 | -31 | 49 | -14 | -6 | -14 | -3 | 7 | 59 | 11 | 20 | 30 | 30 | 28 | 26 | 23 | 19 | 14 | -3 | -12 | 23 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | -1 | 0 | 1 | 0 | 1 | -3 | -1 | -1 | 2 | -3 | -1 | 2 | 1 | -1 |
| Net Profit | -39 | -26 | -28 | -39 | -23 | -24 | -45 | -25 | -31 | 49 | -14 | -7 | -15 | -5 | 8 | 59 | 9 | 20 | 29 | 33 | 29 | 27 | 21 | 22 | 15 | -6 | -13 | 24 |
| EPS in ₹ | -4.32 | -2.93 | -3.11 | -9.52 | -5.55 | -5.98 | -10.96 | -6.06 | -7.57 | 12.10 | -3.40 | -1.61 | -3.68 | -1.32 | 1.86 | 14.49 | 1.85 | 4.30 | 6.18 | 6.81 | 5.79 | 5.37 | 4.10 | 4.40 | 2.94 | -1.13 | -2.49 | 4.69 |
Orchid Pharma
Orchid Pharma
1,000.00
-1.45
(-0.14%)
Market Cap
5,071.91 Cr
PE Ratio
247.32
Volume
30,172.00
Day High - Low
1,009.00 - 982.25
52W High-Low
1,119.80 - 480.00
Key Fundamentals
Market Cap
5,071.91 Cr
EPS
4.05
PE Ratio
247.32
PB Ratio
3.95
Book Value
253.91
EBITDA
34.02
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
7.56
Debt to Equity
0.13
Analyst Rating and Forecast
- By Refinitiv from1 analysts
Actual
Company News
View All News
Orchid Pharma Limited schedules board meeting on Aug 01, 2026, to approve equity share allotment to Dhanuka Laboratories shareholders under amalgamation scheme.
Orchid Pharma Ltd to hold physical investor roadshow in Singapore from July 29-31, 2026. WTD Mridul Dhanuka will lead discussions with no UPSI shared.
Orchid Pharma merger with Dhanuka Labs effective
Jul 10, 2026
Jul 10, 2026Orchid Pharma's merger with Dhanuka Laboratories became effective on July 10, 2026. The NCLT order was filed with the Registrar of Companies.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
2,001.00 | #1 4,80,106.93 | 41.48 | #1 61,673.90 | 12.69 | #1 11,565 | 25.80 | 68.43 | |
7,818.00 | 2,07,543.34 | 80.57 | 11,067.00 | 13.95 | 2,568 | 13.44 | 78.04 | |
4,869.90 | 1,85,235.34 | 86.77 | 13,886.20 | 20.34 | 2,138 | -26.91 | 52.61 | |
1,466.20 | 1,18,446.28 | 35.47 | 29,044.60 | 2.24 | 3,870 | -39.18 | 62.48 | |
1,112.70 | 1,11,963.66 | 21.85 | 27,657.90 | 17.64 | 5,026 | 7.82 | 51.78 | |
2,421.00 | 1,10,696.00 | #1 20.92 | 29,038.90 | #1 26.75 | 5,356 | 87.72 | 53.56 | |
2,570.60 | 1,06,164.75 | 55.24 | 14,636.40 | 14.85 | 1,938 | 31.75 | 58.33 | |
1,778.70 | 96,024.29 | 88.29 | 6,867.80 | 22.01 | 890 | #1 123.93 | 79.83 | |
1,144.80 | 95,552.92 | 29.97 | 35,058.60 | 3.90 | 4,158 | -69.10 | 26.19 | |
1,577.20 | 90,748.60 | 26.38 | 33,384.70 | 3.21 | 3,376 | 1.99 | 59.93 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
-14.54 %
Net Income Growth
-78.06 %
Cash Flow Change
-84.74 %
ROE
-7.01 %
ROCE
-6.21 %
EBITDA Margin (Avg.)
-73.62 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 1,688 | 1,911 |
| Fixed Assets | 1,795 | 1,637 | 1,497 | 1,386 | 1,256 | 858 | 670 | 584 | 573 | 620 | 633 | 1,032 |
| Current Assets | 1,278 | 1,251 | 675 | 679 | 768 | 569 | 550 | 398 | 501 | 791 | 807 | 684 |
| Capital Work in Progress | 282 | 280 | 288 | 272 | 278 | 26 | 7 | 10 | 47 | 31 | 81 | 341 |
| Investments | 0 | 0 | 1 | 1 | 1 | 0 | 15 | 46 | 44 | 46 | 50 | 256 |
| Other Assets | 1,985 | 1,945 | 1,470 | 1,467 | 1,542 | 576 | 544 | 472 | 561 | 857 | 925 | 0 |
| Total Equity & Liabilities | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 1,688 | 1,911 |
| Current Liabilities | 1,123 | 1,338 | 1,510 | 2,013 | 2,346 | 175 | 142 | 241 | 372 | 260 | 286 | 279 |
| Non Current Liabilities | 2,609 | 2,475 | 2,212 | 1,905 | 1,436 | 519 | 442 | 222 | 165 | 124 | 135 | 344 |
| Total Equity | 329 | 49 | -467 | -792 | -704 | 766 | 653 | 647 | 689 | 1,170 | 1,267 | 1,288 |
| Reserve & Surplus | 244 | -40 | -556 | -881 | -793 | 725 | 544 | 538 | 579 | 1,050 | 1,148 | 1,237 |
| Share Capital | 85 | 89 | 89 | 89 | 89 | 41 | 41 | 41 | 41 | 51 | 51 | 51 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 367 | -76 | -240 | 15 | 57 | -2 | -74 | -11 | 18 | -19 | 18 |
| Investing Activities | 1,334 | -2 | -176 | -28 | 46 | 167 | 67 | 113 | -31 | -312 | -27 |
| Operating Activities | -369 | 212 | 401 | 9 | 12 | 81 | 24 | 93 | 18 | 126 | 19 |
| Financing Activities | -597 | -286 | -465 | 33 | -0 | -250 | -165 | -217 | 31 | 167 | 25 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| Promoter | 98.07 % | 90.00 % | 90.00 % | 90.00 % | 90.00 % | 89.96 % | 89.96 % | 89.96 % | 89.96 % | 72.40 % | 72.40 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 4.14 % | 1.96 % | 1.42 % | 1.94 % | 2.53 % | 2.69 % | 1.40 % | 1.56 % | 1.17 % | 0.87 % | 0.81 % |
| DIIs | 1.00 % | 3.44 % | 3.35 % | 3.35 % | 2.97 % | 2.97 % | 2.98 % | 3.94 % | 2.62 % | 13.49 % | 9.88 % | 14.50 % | 17.73 % | 18.93 % | 18.29 % | 18.99 % | 20.10 % | 19.43 % | 19.04 % | 19.39 % | 20.25 % | 20.75 % |
| Government | 0.00 % | 0.00 % | 0.04 % | 0.04 % | 0.04 % | 0.04 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.58 % | 2.34 % | 2.72 % | 2.83 % | 3.34 % | 3.69 % | 3.61 % | 3.44 % | 3.38 % | 3.10 % | 3.85 % | 7.79 % | 7.44 % | 7.16 % | 7.59 % | 6.42 % | 5.11 % | 6.91 % | 7.03 % | 6.76 % | 6.58 % | 6.21 % |
| Others | 0.35 % | 4.22 % | 3.89 % | 3.79 % | 3.65 % | 3.34 % | 3.44 % | 2.66 % | 4.03 % | 11.02 % | 13.87 % | 3.74 % | 3.03 % | 2.65 % | 2.35 % | 2.22 % | 2.27 % | 2.43 % | 2.54 % | 2.84 % | 2.47 % | 2.40 % |
| No of Share Holders | 30,343 | 33,379 | 34,798 | 33,535 | 33,698 | 33,679 | 32,717 | 30,894 | 29,523 | 29,039 | 29,197 | 36,931 | 36,720 | 34,695 | 36,363 | 34,158 | 34,303 | 39,827 | 38,155 | 35,709 | 35,118 | 33,433 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 21 Aug 2024 |  Annual General Meeting | NA | 21 Aug 2024 | 1,147.85 | 1,398.00 |
| 11 Nov 2024 |  Quarterly Result Announcement | NA | 11 Nov 2024 | 1,394.75 | 1,499.45 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 1,457.50 | 1,245.55 |
| 26 May 2025 | Quarterly Result Announcement | NA | 26 May 2025 | 759.20 | 754.40 |
| 26 Jun 2025 |  Extraordinary General Meeting | NA | 26 Jun 2025 | 669.00 | 701.95 |
| 12 Aug 2025 | Quarterly Result Announcement | NA | 12 Aug 2025 | 800.85 | 780.15 |
| 20 Sept 2025 | Annual General Meeting | NA | 20 Sept 2025 | 780.15 | 788.55 |
| 11 Nov 2025 | Quarterly Result Announcement | NA | 11 Nov 2025 | 789.30 | 846.25 |
| 11 Feb 2026 | Quarterly Result Announcement | NA | 11 Feb 2026 | 688.40 | 687.80 |
| 25 May 2026 | Quarterly Result Announcement | NA | 25 May 2026 | 713.10 | 708.00 |
| 23 Jul 2026 |  Merger - Demerger | 5:161 | 23 Jul 2026 | 1,001.45 | 1,001.45 |
Announcements
Board Meeting Intimation for Prior Intimation Of Board Meeting Scheduled To Be Held On August 01 20261 day ago
1 day agoIntimation Regarding Investor Roadshow5 days ago
5 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 11, 2026
Jul 11, 2026Corporate Action For Fixation Of Record DateJul 10, 2026
Jul 10, 2026Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationJul 10, 2026
Jul 10, 2026Board Meeting Outcome for Intimation Under Regulations 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended ("SEBI Listing Regulations").Jul 10, 2026
Jul 10, 2026Update Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited (Amalgamating Company) With Orchid Pharma Limited (Amalgamated Company/Company) And Their Respective Shareholders
And Creditors (The Scheme) Under Regulation 30 Of SEBI (ListingJul 10, 2026
Jul 10, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 07, 2026
Jul 07, 2026Closure of Trading WindowJun 26, 2026
Jun 26, 2026Update Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited And Orchid Pharma LimitedJun 12, 2026
Jun 12, 2026Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderJun 11, 2026
Jun 11, 2026Update Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited (Amalgamating Company) With Orchid Pharma Limited (Amalgamated Company) And Their Respective Shareholders And Creditors (The Scheme) Under Regulation 30 Of SEBI (Listing ObligatiJun 05, 2026
Jun 05, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 01, 2026
Jun 01, 2026Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2026
May 30, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 26, 2026
May 26, 2026Announcement under Regulation 30 (LODR)-Investor PresentationMay 26, 2026
May 26, 2026Appointment Of Internal Auditor Of The CompanyMay 25, 2026
May 25, 2026Statement Of Deviation Or Variation For The Quarter And Financial Year Ended On March 31 2026May 25, 2026
May 25, 2026Board Meeting Outcome For Outcome Of Board Meeting For Considering And Approving Annual Audited Financial Results For The Quarter And F.Y. Ended On March 31 2026May 25, 2026
May 25, 2026Board Meeting Outcome for Board Meeting Outcome For Outcome Of Board Meeting For Considering And Approving Annual Audited Financial Results For The Quarter And F.Y. Ended On March 31 2026.May 25, 2026
May 25, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 19, 2026
May 19, 2026Board Meeting Intimation for Approval Of Audited Financial Results (Standalone & Consolidated) Of The Company For The Quarter-IV And Financial Year Ended On March 31 2026May 19, 2026
May 19, 2026Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 14, 2026
May 14, 2026Intimation Under Regulation 30Apr 11, 2026
Apr 11, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 09, 2026
Apr 09, 2026Investor Roadshow Scheduled To Be Held On April 10 2026.Apr 07, 2026
Apr 07, 2026Announcement under Regulation 30 (LODR)-Credit RatingApr 02, 2026
Apr 02, 2026Closure of Trading WindowMar 27, 2026
Mar 27, 2026Update Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited (Amalgamating Company) With Orchid Pharma Limited (Amalgamated Company) And Their Respective Shareholders And Creditors (The Scheme) Under Regulation 30 Of SEBI (Listing ObligatiMar 18, 2026
Mar 18, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 16, 2026
Feb 16, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 11, 2026
Feb 11, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 11, 2026
Feb 11, 2026Board Meeting Outcome for Unaudited Limited Review Standalone & Consolidated Financial Results For The Quarter And Year To Date Ended On December 31 2025Feb 11, 2026
Feb 11, 2026Quarterly ResultsFeb 11, 2026
Feb 11, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 06, 2026
Feb 06, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 06, 2026
Feb 06, 2026Board Meeting Intimation for The Quarter-III Of Financial Year 2025-26 Ended On December 2025.Feb 06, 2026
Feb 06, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 08, 2026
Jan 08, 2026Closure of Trading WindowDec 29, 2025
Dec 29, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 17, 2025
Nov 17, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 11, 2025
Nov 11, 2025Unaudited Limited Reviewed Financial Results For Q-2 Of F.Y.2025-26Nov 11, 2025
Nov 11, 2025Board Meeting Outcome for Outcome Of Board Meeting- Q2- F.Y.2025-26Nov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 05, 2025
Nov 05, 2025Board Meeting Intimation for Prior Intimation Of Board Meeting Scheduled To Be Held On November 11 2025
Nov 05, 2025
Nov 05, 2025Company Response On The Spurt In Volume Of Security Across ExchangesNov 04, 2025
Nov 04, 2025Clarification sought from Orchid Pharma LtdNov 04, 2025
Nov 04, 2025Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 53.20
ATR(14)
Less Volatile 50.38
STOCH(9,6)
Oversold 19.46
STOCH RSI(14)
Oversold 18.25
MACD(12,26)
Bearish -12.19
ADX(14)
Strong Trend 31.11
UO(9)
Bearish 40.65
ROC(12)
Downtrend And Accelerating -0.59
WillR(14)
Neutral -70.51
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
